First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

AstraZeneca and partner Merck & Co look set to have a much narrower label for their PARP inhibitor Lynparza in prostate cancer than they were hoping for in the US. The FDA’s Oncologic Drugs ...

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...

AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast cancer – the first drug in the class to show that in a clinical trial.

Neoplastic Agents Market Report 2025" has been added to ResearchAndMarkets.com's offering.This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, ...

The Breast Cancer market is undergoing significant expansion, driven by increasing disease prevalence and the introduction of innovative therapeutic options from companies such as ...

Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

One woman's story of literal strength illustrates how ovarian cancer symptoms can be missed—and the lighthearted recovery ...

Mission was built on the work of Steve Jackson, the University of Cambridge professor perhaps best known for discovering Lynparza ... of the study showed the drug candidate “has a good safety ...